Please login to the form below

Not currently logged in
Email:
Password:

David Colpman joins Forendo Pharma’s board

He becomes a non-executive director

David ColpmanForendo Pharma, a drug development company, has appointed David Colpman to its board of directors.

Colpman, who becomes the group’s non-executive director, brings with him a career of more than 25 years in pharma and biotech business development and strategy.

He said: “I see great opportunities for Forendo, and look forward to working with the experienced team in the company.”

His previous roles include head of global business development at Shire and business development and commercial positions at Glaxo Wellcome - now GlaxoSmithKline - and Novo Nordisk.

Risto Lammintausta, chief executive officer of Forendo Pharma, said: “We are delighted to welcome David with his broad experience in the industry that will be of significant benefit to Forendo.

“His insights and expertise will be very helpful as we continue to evaluate the commercial alternative of our programmes.”

29th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...
International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...

Infographics